InvestorsObserver
×
News Home

Where Will Indaptus Therapeutics Inc (INDP) Stock Go Next After It Is Higher By 2.62% in a Week?

Monday, July 10, 2023 10:23 AM | InvestorsObserver Analysts

Mentioned in this article

Where Will Indaptus Therapeutics Inc (INDP) Stock Go Next After It Is Higher By 2.62% in a Week?

Indaptus Therapeutics Inc (INDP) stock is higher by 2.62% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bullish
Indaptus Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on INDP!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With INDP Stock Today?

Indaptus Therapeutics Inc (INDP) stock is unmoved 0.26% while the S&P 500 has risen 0.26% as of 10:11 AM on Monday, Jul 10. INDP is flat $0.00 from the previous closing price of $1.95 on volume of 5,173 shares. Over the past year the S&P 500 is higher by 14.43% while INDP is lower by -37.38%. INDP lost -$1.83 per share in the over the last 12 months. To screen for more stocks like Indaptus Therapeutics Inc click here.

More About Indaptus Therapeutics Inc

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. Click Here to get the full Stock Report for Indaptus Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App